Department of Cardiology, Shanghai Deji Hospital, Shanghai, 200331, China.
Department of Cardiology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200131, China.
J Nanosci Nanotechnol. 2021 Feb 1;21(2):1378-1384. doi: 10.1166/jnn.2021.18652.
Complications of diabetes are the main cause of death and disability in diabetic patients. Cardiovascular diseases, especially diabetic cardiomyopathy, are one of the major complications and causes of death in type 2 diabetes. Peptide drugs have a better effect on improving cellular oxidative damage, reducing tissue inflammation and inhibiting intracellular calcium overload. The application of nanotechnology to the preparation of peptide drugs and myocardial injury can effectively improve myocardial stun, arrhythmia and myocardial systolic dysfunction in patients with type 2 diabetes. The use of nanotechnology to develop more stable Glucagon-like peptide 1 analogues or sustained-release preparations, improve patient compliance and improve the efficacy of diabetes, is of great significance for the prevention and treatment of diabetic cardiomyopathy. Therefore, this study used nanotechnology to prepare PLGA-GLP-1 nanoparticles using polyglycolic acid glycolic acid as a drug carrier, which achieved long-acting drug and its morphology by transmission electron microscopy. At the same time, this study explored the anti-cardiomyocyte injury and anti-myocardial damage of PLGA-GLP-1 nanocomposite peptide and its molecular mechanism by using animal models and cell models. Experimental studies have shown that PLGA-GLP-1 nanocomposite peptide has a protective effect on myocardial injury in diabetic rats. Its mechanism is related to the PLGA-GLP-1 nanocomposite peptide enhancing the body's antioxidant capacity, anti-cardiomyocyte apoptosis, and promoting mitochondrial DNA repair in cardiomyocytes.
糖尿病并发症是糖尿病患者死亡和残疾的主要原因。心血管疾病，尤其是糖尿病性心肌病，是 2 型糖尿病的主要并发症和死亡原因之一。肽类药物在改善细胞氧化损伤、减轻组织炎症和抑制细胞内钙超载方面有较好的作用。将纳米技术应用于肽类药物和心肌损伤的制备中，可以有效改善 2 型糖尿病患者的心肌顿抑、心律失常和心肌收缩功能障碍。利用纳米技术开发更稳定的胰高血糖素样肽 1 类似物或缓释制剂，提高患者顺应性，改善糖尿病疗效，对于防治糖尿病性心肌病具有重要意义。因此，本研究采用纳米技术，以聚乳酸-乙醇酸为药物载体，制备 PLGA-GLP-1 纳米粒，通过透射电子显微镜观察其形态和长效药物作用。同时，本研究通过动物模型和细胞模型探讨了 PLGA-GLP-1 纳米复合肽对心肌细胞损伤的保护作用及其分子机制。实验研究表明，PLGA-GLP-1 纳米复合肽对糖尿病大鼠心肌损伤具有保护作用，其机制与 PLGA-GLP-1 纳米复合肽增强机体抗氧化能力、抗心肌细胞凋亡、促进心肌细胞线粒体 DNA 修复有关。
